Universal Health Services, Inc. Reports 2014 Fourth Quarter And Full Year Earnings And 2015 Earnings Guidance
Consolidated Results of Operations, As Reported - Three and twelve-month periods ended December 31, 2014 and 2013:
KING OF PRUSSIA, Pa.
Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience
New Patient Athlete™ Program Demonstrates Comprehensive Approach to Driving Sustained Behavior Change and Improved Outcomes
Launch of the Anti-Cancer Agent / BRAF Inhibitor "Zelboraf®" - Contribution to the Treatment of Melanoma by Personalized Healthcare -
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C
THOUSAND OAKS, Calif., Feb.
ABRAXANE® Now Reimbursed in Italy as a First-Line Treatment of Adult Patients with Metastatic Pancreatic Cancer
TWi Pharmaceuticals Announces That It Will Sell Its Products in the U.S. Market, Originally Planned to Be Sold by Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire
On and off the track, Reed shows that diabetes doesn't stop him from living his dreams